Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma.

Abstract:

:We studied 174 consecutive patients with relapsed refractory multiple myeloma (MM) enrolled on a phase II clinical trial of pomalidomide plus low-dose dexamethasone at Mayo Clinic. Extramedullary disease (EMD) was present at the time of trial entry in 7.5% (13 of 174 patients). The rate of EMD in the first 3 years following diagnosis of MM was 3%. The response of EMD to pomalidomide plus low-dose dexamethasone included two complete and two partial responses among the 13 patients (response rate, 31%). Overall survival measured from trial entry was significantly shorter for patients with treatment-emergent EMD compared with those who did not have EMD, (median 16 months versus not reached, P=0.002).

journal_name

Leukemia

journal_title

Leukemia

authors

Short KD,Rajkumar SV,Larson D,Buadi F,Hayman S,Dispenzieri A,Gertz M,Kumar S,Mikhael J,Roy V,Kyle RA,Lacy MQ

doi

10.1038/leu.2011.29

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

906-8

issue

6

eissn

0887-6924

issn

1476-5551

pii

leu201129

journal_volume

25

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Potential role for concurrent abnormalities of the cyclin D1, p16CDKN2 and p15CDKN2B genes in certain B cell non-Hodgkin's lymphomas. Functional studies in a cell line (Granta 519).

    abstract::Abnormalities of several cell-cycle regulatory genes including cyclin D1, p16CDKN2 and p15CDKN2B have been described in B cell non-Hodgkin's lymphoma (B-NHL). We describe a new B-NHL cell line (Granta 519), with concurrent abnormalities of the cyclin D1, pl6CDKN2 and pl5CDKN2B genes. An independent clinical case of ma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400555

    authors: Jadayel DM,Lukas J,Nacheva E,Bartkova J,Stranks G,De Schouwer PJ,Lens D,Bartek J,Dyer MJ,Kruger AR,Catovsky D

    更新日期:1997-01-01 00:00:00

  • Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.

    abstract::Population-based studies of classical Hodgkin lymphoma (cHL) in contemporary clinical practice are scarce. The aim of this nationwide population-based study is to assess trends in primary therapy and relative survival (RS) during 1989-2017. We included 9,985 patients with cHL. Radiotherapy alone was virtually not appl...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-0875-0

    authors: Driessen J,Visser O,Zijlstra JM,Lugtenburg PJ,Plattel WJ,Kersten MJ,Dinmohamed AG

    更新日期:2020-05-28 00:00:00

  • CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.

    abstract::CD44 variant isoforms (CD44v) have been shown to be important factors in adverse prognosis in hematological malignancies. To investigate whether CD44 expression is associated with malignant transformation in multiple myeloma, RNA and protein expression of CD44 standard (CD44s) and CD44v4, v6, v9, v10 containing isofor...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401179

    authors: van Driel M,Günthert U,Stauder R,Joling P,Lokhorst HM,Bloem AC

    更新日期:1998-11-01 00:00:00

  • SETD2-mediated crosstalk between H3K36me3 and H3K79me2 in MLL-rearranged leukemia.

    abstract::Previously, we identified SETD2 loss-of-function mutations in 22% of MLL-rearranged (MLLr) acute leukemia patients, implicating a mechanism for cooperativity between SETD2 mutations and MLL fusions. However, the detailed mechanism of how SETD2-H3K36me3 downregulation accelerates MLLr leukemia remains unclear. Here, we...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.339

    authors: Bu J,Chen A,Yan X,He F,Dong Y,Zhou Y,He J,Zhan D,Lin P,Hayashi Y,Sun Y,Zhang Y,Xiao Z,Grimes HL,Wang QF,Huang G

    更新日期:2018-04-01 00:00:00

  • Establishment and characterization of a murine megakaryoblastic cell line growing in protein-free culture (L8057Y5).

    abstract::A murine megakaryoblastic cell line growing in protein-free culture (L8057Y5) was established from an experimentally induced murine leukemia (MK8057). Most of the Y5 cells were small and blast-like, with 2-4N in DNA content. Also, large cells possessing a lobulated nucleus characteristic of megakaryocytes, which showe...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Sasaki H,Kajigaya Y,Hirabayashi Y,Funabiki T,Inoue T,Yokota T,Ikuta K,Arai K,Matsuyama S

    更新日期:1991-05-01 00:00:00

  • Inducible production of macrophage colony-stimulating factor (CSF-1) by malignant and normal human T cells.

    abstract::The CEM-ON malignant T cell line and long-term cultured normal T cells can be induced to release CSF-1 in their culture supernatants. Chemical inducers (PMA + A23187) and, more interestingly, cytokines (tumor necrosis factor alpha (TNF alpha) and interleukin-1 alpha (IL-1 alpha)), as well as physiological (antigen + I...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Praloran V,Gascan H,Papin S,Chevalier S,Trossaërt M,Boursier MC

    更新日期:1990-06-01 00:00:00

  • Altered transcription of the stem cell leukemia gene in myelofibrosis with myeloid metaplasia.

    abstract::An increased number of circulating CD34+ hematopoietic progenitors with a prominent proliferation of the megakaryocytic (MK) population are the hallmarks of the myeloproliferation in myelofibrosis with myeloid metaplasia (MMM). Analyzing the potential contribution of the stem cell leukemia (SCL) gene in MMM myeloproli...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403089

    authors: Steunou V,Le Bousse-Kerdilès MC,Colin-Micouin A,Clay D,Chevillard S,Martyré MC,French INSERM Research Network on Myelofibrosis Myeloid Metaplasia.

    更新日期:2003-10-01 00:00:00

  • Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p16, MLL, and ETV6 gene abnormalities: results of St Jude Total Therapy Study XII.

    abstract::To determine the frequency and prognostic significance of recently described genetic lesions in pediatric acute lymphoblastic leukemia (ALL), all cases with available leukemic cell samples treated on St Jude Study XII were analyzed by molecular techniques for alterations of the p16, MLL and ETV6 genes. Homozygous p16 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400779

    authors: Rubnitz JE,Behm FG,Pui CH,Evans WE,Relling MV,Raimondi SC,Harrison PL,Sandlund JT,Ribeiro RC,Grosveld G,Downing JR

    更新日期:1997-08-01 00:00:00

  • Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.

    abstract::An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title:Leukemia

    pub_type: 已发布勘误

    doi:10.1038/s41375-020-0821-1

    authors: Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

    更新日期:2020-10-01 00:00:00

  • The proteasome: a novel target for cancer chemotherapy.

    abstract::The ubiquitin-proteasome system is an important regulator of cell growth and apoptosis. The potential of specific proteasome inhibitors to act as novel anti-cancer agents is currently under intensive investigation. Several proteasome inhibitors exert anti-tumour activity in vivo and potently induce apoptosis in tumour...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2402417

    authors: Almond JB,Cohen GM

    更新日期:2002-04-01 00:00:00

  • Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture.

    abstract::Interleukin 12 (IL-12; natural killer cell stimulatory factor, NKSF; cytotoxic lymphocyte maturation factor, CLMF) was studied for its effects on the survival and generation of hemopoietic progenitors (CFU-C, CAFC day 7-14) and long-term culture initiating stem cells (CAFC day 28-35) by post-5-fluorouracil (FU) bone m...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Ploemacher RE,van Soest PL,Voorwinden H,Boudewijn A

    更新日期:1993-09-01 00:00:00

  • BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996).

    abstract::Modern treatment strategies, consisting of intensive chemotherapy and cranial irradiation, have remarkably improved the prognosis for children with acute lymphoblastic leukemia. However, patients with a potential for cure are at risk of severe acute and late adverse effects of treatment. Furthermore, in 25-30% of pati...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1038/sj.leu.2402489

    authors: Kamps WA,Bökkerink JP,Hakvoort-Cammel FG,Veerman AJ,Weening RS,van Wering ER,van Weerden JF,Hermans J,Slater R,van den Berg E,Kroes WG,van der Does-van den Berg A

    更新日期:2002-06-01 00:00:00

  • Pediatric acute myelogenous leukemia cells express IL-6 receptors and are sensitive to a recombinant IL6-Pseudomonas exotoxin.

    abstract::We have studied IL-6 receptor (IL-6R) expression on AML cells from 15 pediatric patients by immunocytochemistry/flow cytometry, reverse-transcription polymerase chain reaction, and Scatchard analysis. High-affinity IL-6R were detected on leukemic cells from 12 (80%) patients. Binding sites per cell ranged from 140 to ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2400914

    authors: Boayue KB,Gu L,Yeager AM,Kreitman RJ,Findley HW

    更新日期:1998-02-01 00:00:00

  • Prevention of T-cell lymphoma in AKR/J mice.

    abstract::Injection of a dual tropic virus (DTV) isolated from a T cell lymphoma AKR/J mice into the thymus of 14 day old AKR/J puppies accelerates lymphoma development; 90-100% of the injected mice develop the disease within 120 days. In contrast a cell free centrifuge CFC-666 prepared B cell lymphoma of AKR/J origin injected ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Peled A,Haran-Ghera N

    更新日期:1988-12-01 00:00:00

  • High level of cannabinoid receptor 1, absence of regulator of G protein signalling 13 and differential expression of Cyclin D1 in mantle cell lymphoma.

    abstract::Mantle cell lymphoma (MCL) is a moderately aggressive B-cell lymphoma that responds poorly to currently used therapeutic protocols. In order to identify tumour characteristics that improve the understanding of biology of MCL, analysis of oligonucleotide microarrays were used to define specific gene expression profiles...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403057

    authors: Islam TC,Asplund AC,Lindvall JM,Nygren L,Liden J,Kimby E,Christensson B,Smith CI,Sander B

    更新日期:2003-09-01 00:00:00

  • Simple and reliably sensitive diagnosis and monitoring of Philadelphia chromosome-positive cells in chronic myeloid leukemia by interphase fluorescence in situ hybridization of peripheral blood cells.

    abstract::Philadelphia (Ph) chromosome or the bcr/abl fusion gene is the hallmark of chronic myeloid leukemia (CML) and serves as a prognostic marker during its treatment. Its detection has been primarily done by karyotype analysis of bone marrow cells. The major limitation of the karyotypic technique is an absolute need for me...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401383

    authors: Yanagi M,Shinjo K,Takeshita A,Tobita T,Yano K,Kobayashi M,Terasaki H,Naoe T,Ohnishi K,Ohno R

    更新日期:1999-04-01 00:00:00

  • Detection of trisomy 8 on blood smears using fluorescence in situ hybridization.

    abstract::In this study, fluorescence in situ hybridization (ISH) with an alphoid probe was used for the detection of trisomy 8 on archival blood smears (BS). The results were compared with hybridization experiments performed on methanol/acetic acid fixed cells of cytogenetic preparations (CP) which are widely used for ISH. Fiv...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bentz M,Schröder M,Herz M,Stilgenbauer S,Lichter P,Döhner H

    更新日期:1993-05-01 00:00:00

  • Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia.

    abstract::We have analyzed the expression of Tdt and CD7 in 335 cases of unequivocal acute myeloid leukemia (AML). Tdt was expressed in 80 (25%) of 321 evaluable cases. Twenty-six of 77 (34%) Tdt+ patients assessable for response, entered complete remission (CR) vs 121 of 209 (58%) Tdt- cases (P < 0.001). CD7 was expressed in 1...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401067

    authors: Venditti A,Del Poeta G,Buccisano F,Tamburini A,Cox-Froncillo MC,Aronica G,Bruno A,Del Moro B,Epiceno AM,Battaglia A,Forte L,Postorino M,Cordero V,Santinelli S,Amadori S

    更新日期:1998-07-01 00:00:00

  • Proteomic analysis of childhood leukemia.

    abstract::Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing differen...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2403897

    authors: Hegedus CM,Gunn L,Skibola CF,Zhang L,Shiao R,Fu S,Dalmasso EA,Metayer C,Dahl GV,Buffler PA,Smith MT

    更新日期:2005-10-01 00:00:00

  • Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.

    abstract::Acute promyelocytic leukemia (APL) cells express different types of procoagulant activity (PCA), including tissue factor (TF), and cancer procoagulant (CP). The aim of this study was to investigate whether the NB4 cell line, the first ever isolated human APL line, with the typical t(15;17) chromosomal balance transloc...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Falanga A,Consonni R,Marchetti M,Mielicki WP,Rambaldi A,Lanotte M,Gordon SG,Barbui T

    更新日期:1994-01-01 00:00:00

  • Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.

    abstract::We investigated the hypothesis that gemtuzumab ozogamicin (GO), an anti-CD33 immunotoxin would improve the efficacy of fludarabine/melphalan as a preparative regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in a phase I/II trial. Toxicity was defined as grades III-IV organ damage, engraftment fail...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2405014

    authors: de Lima M,Champlin RE,Thall PF,Wang X,Martin TG 3rd,Cook JD,McCormick G,Qazilbash M,Kebriaei P,Couriel D,Shpall EJ,Khouri I,Anderlini P,Hosing C,Chan KW,Andersson BS,Patah PA,Caldera Z,Jabbour E,Giralt S

    更新日期:2008-02-01 00:00:00

  • A diagnostic biochip for the comprehensive analysis of MLL translocations in acute leukemia.

    abstract::Reciprocal rearrangements of the MLL gene are among the most common chromosomal abnormalities in both Acute Lymphoblastic and Myeloid Leukemia. The MLL gene, located on the 11q23 chromosomal band, is involved in more than 40 recurrent translocations. In the present study, we describe the development and validation of ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403439

    authors: Maroc N,Morel A,Beillard E,De La Chapelle AL,Fund X,Mozziconacci MJ,Dupont M,Cayuela JM,Gabert J,Koki A,Fert V,Hermitte F

    更新日期:2004-09-01 00:00:00

  • Identification of a favorable subgroup of patients with generalized immunocytomas by follicular dendritic cells.

    abstract::In the present study, 89 patients with generalized immunocytoma were analyzed retrospectively for the prognostic influence of clinical features and of immunophenotype using bone marrow biopsies. Univariate analysis selected the following variables as significant for survival: age over 60 years (p = 0.021), Rai and Bin...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Eisterer W,Hilbe W,Fend F,Ludescher C,Falk M,Thaler J

    更新日期:1995-02-01 00:00:00

  • Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio.

    abstract::Post-remission treatment (PRT) in patients with cytogenetically normal (CN) acute myeloid leukemia (AML) in first complete remission (CR1) is debated. We studied 521 patients with CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was available, including the FLT3-ITD allelic ratio. PRT consisted of reduce...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.183

    authors: Versluis J,In 't Hout FE,Devillier R,van Putten WL,Manz MG,Vekemans MC,Legdeur MC,Passweg JR,Maertens J,Kuball J,Biemond BJ,Valk PJ,van der Reijden BA,Meloni G,Schouten HC,Vellenga E,Pabst T,Willemze R,Löwenberg B,O

    更新日期:2017-01-01 00:00:00

  • Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia.

    abstract::We analyzed the long-term outcome of 1011 patients treated in five successive clinical trials (Total Therapy Studies 11, 12, 13A, 13B, and 14) between 1984 and 1999. The event-free survival improved significantly (P=0.003) from the first two trials conducted in the 1980s to the three more recent trials conducted in th...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/leu.2009.252

    authors: Pui CH,Pei D,Sandlund JT,Ribeiro RC,Rubnitz JE,Raimondi SC,Onciu M,Campana D,Kun LE,Jeha S,Cheng C,Howard SC,Metzger ML,Bhojwani D,Downing JR,Evans WE,Relling MV

    更新日期:2010-02-01 00:00:00

  • Clinical and cytogenetic correlations of abnormal megakaryocytopoiesis in patients with acute leukemia and chronic myelogenous leukemia in blast crisis.

    abstract::It has been suggested that abnormalities of chromosome 3 at bands q21 and q26 are associated with the presence of increased numbers of abnormal megakaryocytes in patients with hematologic malignancies. The pretreatment bone marrows of 287 patients with leukemia (acute myeloid leukemia (AML), 225 patients; acute lympho...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Lee EJ,Schiffer CA,Tomiyasu T,Testa JR

    更新日期:1990-05-01 00:00:00

  • Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia.

    abstract::Deletions from the derivative chromosome 9, der(9), of the translocation, t(9;22)(q34;q11), at the site of the ABL/BCR fusion gene, have been demonstrated by fluorescence in situ hybridisation (FISH), in both Philadelphia chromosome (Ph)-positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL)....

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403629

    authors: Robinson HM,Martineau M,Harris RL,Barber KE,Jalali GR,Moorman AV,Strefford JC,Broadfield ZJ,Cheung KL,Harrison CJ

    更新日期:2005-04-01 00:00:00

  • Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity.

    abstract::Identification of agents that target human leukemia stem cells is an important consideration for the development of new therapies. The present study demonstrates that rocaglamide and silvestrol, closely related natural products from the flavagline class of compounds, are able to preferentially kill functionally define...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.93

    authors: Callahan KP,Minhajuddin M,Corbett C,Lagadinou ED,Rossi RM,Grose V,Balys MM,Pan L,Jacob S,Frontier A,Grever MR,Lucas DM,Kinghorn AD,Liesveld JL,Becker MW,Jordan CT

    更新日期:2014-10-01 00:00:00

  • Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma.

    abstract::In this report, a panel of European myeloma experts discuss the role of pomalidomide in the treatment of relapsed and refractory multiple myeloma (RRMM). Based on the available evidence, the combination of pomalidomide and low-dose dexamethasone is a well-tolerated and effective treatment option for patients with RRMM...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/leu.2014.60

    authors: Dimopoulos MA,Leleu X,Palumbo A,Moreau P,Delforge M,Cavo M,Ludwig H,Morgan GJ,Davies FE,Sonneveld P,Schey SA,Zweegman S,Hansson M,Weisel K,Mateos MV,Facon T,Miguel JF

    更新日期:2014-08-01 00:00:00

  • Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

    abstract::The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.71

    authors: Itzykson R,Kosmider O,Cluzeau T,Mansat-De Mas V,Dreyfus F,Beyne-Rauzy O,Quesnel B,Vey N,Gelsi-Boyer V,Raynaud S,Preudhomme C,Adès L,Fenaux P,Fontenay M,Groupe Francophone des Myelodysplasies (GFM).

    更新日期:2011-07-01 00:00:00